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Gravin, an autoantigen recognized by serum from myasthenia
gravis patients, is a kinase scaffold protein
J. Brian Nauert*, Theresa M. Klauck, Lorene K. Langeberg and John D. Scott
Background: Subcellular targeting of protein kinases and phosphatases
provides a mechanism for co-localizing these enzymes with their preferred
substrates. A recently identified mammalian scaffold protein, AKAP79, controls
the location of two broad-specificity kinases and a phosphatase. 
Results: We have identified and characterized another mammalian scaffold
protein which coordinates the location of protein kinase A and protein kinase C.
We isolated a cDNA encoding a 250 kDa A-kinase anchoring protein (AKAP)
called gravin, which was originally identified as a cytoplasmic antigen recognized
by myasthenia gravis sera. Sequence homology to proteins that are known to
bind protein kinase C suggests that gravin also binds this kinase. Studies of
binding in vitro show that residues 1526–1780 of gravin bind the regulatory
subunit (RII) of protein kinase A with high affinity, and residues 265–556 bind
protein kinase C. Gravin expression in human erythroleukemia cells can be
induced with phorbol ester, resulting in the detection of a 250 kDa RII- and PKC-
binding protein. Immunolocalization experiments show that gravin is
concentrated at the cell periphery and is enriched in filopodia. Gravin staining is
coincident with an AKAP detected by an in situ RII-overlay assay, and a
PKA–gravin complex can be isolated from human erythroleukemia cells. 
Conclusions: We present biochemical evidence that gravin forms part of a
signaling scaffold, and propose that protein kinases A and C may participate in
the coordination of signal transduction events in the filopodia of human
erythroleukemia cells.
Background
The intracellular transduction of signals from the plasma
membrane to specific subcellular compartments is a
complex and highly regulated series of events controlling
essential physiological processes [1]. Perhaps the most
graphic demonstration of the central place signaling path-
ways have in cellular homeostasis is provided by the many
transforming oncogenes that encode mutated signal trans-
duction components, such as low molecular weight GTP-
binding proteins, protein kinases or phosphatases [2].
Now that many of these genes have been identified,
research has begun to focus on how the enzymes they
encode interact to control cellular events. A critical
element is the subcellular location of each signaling
enzyme [3]. For example, the correct intracellular target-
ing of kinases and phosphatases directs these enzymes to
their preferred substrates and reduces indiscriminate
background phosphorylation and dephosphorylation that
would otherwise ensue upon basal activation [4]. 
Targeting of kinases and phosphatases is achieved
through association with targeting proteins or subunits
(see [3,5,6] for reviews). For example, tyrosine kinase and
tyrosine phosphatase activity can be coupled to down-
stream cytoplasmic enzymes through adaptor proteins that
contain Src homology 2 (SH2) and SH3 domains [7].
Modular adaptor proteins, such as Grb2, p85, IRS-1, Crk
and Nck, consist of a single SH2 domain that recognizes
certain phosphotyrosyl residues on signaling enzymes,
coupled to two SH3 domains that bind to a Pro–X–X–Pro
motif (where X is any amino acid) on a separate set of
target proteins [7]. Similarly, many phosphodiesterases,
phospholipases, kinases, phosphatases and heterotrimeric
G proteins are targeted by specific membrane-targeting
motifs such as the LIM, C2, pleckstrin-homology and
lipid-anchoring domains [8,9]. As a result of these interac-
tions, signaling complexes assemble around receptor
kinases or scaffold proteins to mediate cellular processes
including growth factor signaling events, insulin action
and immune-cell function.
Until recently, kinases and phosphatases stimulated by
second messengers were thought to be localized through
association with individual targeting proteins. For
example, three classes of phosphatase-targeting subunits
have been identified which are specific for either protein
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phosphatase-1 (PP-1) [5,10], PP-2A [11,12] or PP-2B
[13,14]. Likewise, three classes of protein responsible for
targeting protein kinase C (PKC) have been identified
[6,15,16], whereas compartmentalization of the cAMP-
dependent protein kinase (protein kinase A, PKA) is
achieved through interaction of its regulatory (R) subunits
with a functionally related family of 30 or so A-kinase-
anchoring proteins, called AKAPs (reviewed in [17,18]).
On the basis of these observations, we have proposed that
anchoring proteins confer specificity on serine/threonine
kinases and phosphatases, by directing them to discrete
subcellular sites where they have restricted access to
certain substrates and are optimally positioned to respond
to fluctuations in the levels of second messengers [3].
A variation on this theme is the recent identification of
multivalent binding proteins that coordinate the location
of serine/threonine kinase and phosphatase signaling com-
plexes [19]. For example, the pheromone-mediated
mating response in yeast is initiated through a G-protein-
linked receptor that activates a yeast homologue of the
mammalian mitogen-activated protein kinase (MAP
kinase) cascade [20]. This process proceeds efficiently
because each enzyme in the cascade is associated with a
scaffold protein called Ste5 [21–23]. Clustering of succes-
sive members in the MAP kinase cascade is optimal for
the tight regulation of the pathway and prevents cross-talk
between the six functionally distinct MAP kinase modules
in yeast [20]. Another example of a multivalent binding
protein is AKAP79, which targets PKA, PKC and PP-2B at
the postsynaptic densities of mammalian synapses [24].
The structure of AKAP79 is modular and resembles that
of Ste5, in that deletion analysis, peptide studies and co-
precipitation techniques have demonstrated that each
anchored enzyme binds to a distinct region of the anchor-
ing protein [14,24]. Targeting of the AKAP79 signaling
complex to the postsynaptic densities suggests a model for
reversible phosphorylation in which the opposing effects
of kinase and phosphatase action are co-localized by a
common anchoring protein [25].
In this report, we describe the cloning and characterization
of a second multivalent kinase-scaffold protein called
gravin. A fragment of gravin was originally identified as a
cytoplasmic antigen recognized by sera from patients with
myasthenia gravis [26]. We now show that distinct regions
of gravin show homology to AKAPs and proteins that are
substrates for, and/or bind to, PKC. Binding studies in vitro
have mapped the binding sites for both A and C kinases,
Figure 1
The sequence of gravin. (a) The deduced amino-acid sequence of the
cDNA encoding gravin. (b) Sequence homology between gravin and
SSeCKs/clone 72. Identical residues are indicated by bars, and amino
acids are presented in the one letter code. The Genbank accession
number for the gravin sequence is U81607.
HUM GRAVIN     1  MGAGSSTEQRSPEQPPEGSSTPAEPEPSGGGPSAEAAPDTTADPAIAASDPATKLLQKNGQLSTI   65
                  |||||||||||||||  || || |   || || |||      ||| |  |||||||||||||  
CLONE 72       1  MGAGSSTEQRSPEQPA GSDTPSELVLSGHGPAAEASGAAG DPADA  DPATKLPQKNGQLSSV   61

HUM GRAVIN    66  NGVAEQDELSLQEGDLNGQKGALNGQGALNSQEEEEVIVTEVGQRDSEDVSERDSDKEMATKSAV  130
                  ||||||     ||   | | |          | ||||    |||| |||| | |  |||  |
CLONE 72      62  NGVAEQGDVHVQE E N QEG          Q EEEVVDEDVGQRESEDVREKDRVEEMAANSTA  112

HUM GRAVIN   131  VHDITDDGQEENRN IEQIPSSESNLEELTQPTESQANDIGFKKVFKFVGFKFTVKKDKTEKPDT  194
                  | ||| |||||    ||||| || | ||  || |||||| ||||||||||||||||||| || ||
CLONE 72     113  VEDITKDGQEETSEIIEQIPASENNVEEMVQPAESQANDVGFKKVFKFVGFKFTVKKDKNEKSDT  177

HUM GRAVIN   195  VQLLTVKKDEGEGA A  GAGDHQDPSL GA GEAASKESEPKQSTEKPEETLKREQSHAEISPP  254
                  |||||||||||||| |  |||||| ||   | || |||||| |||||| | ||| |||  || |
CLONE 72     178  VQLLTVKKDEGEGAEASVGAGDHQEPSVETAVGESASKESELKQSTEKQEGTLKQEQSSTEI PL  241

HUM GRAVIN   255   AESGQAVEEC KEEGEEKQEKEPSKSAESPTSPVTSETGSTFKKFFTQGWAGWRKKTSFRKPKE  317
                   ||| || ||  | |||||||||| || ||| ||| ||| | |||||| ||||||||||| | ||
CLONE 72     242  QAESDQAAEEEAKDEGEEKQEKEPTKSPESPSSPVNSETTSSFKKFFTHGWAGWRKKTSFKKSKE  306

HUM GRAVIN   318  DEVEASEKKKEQEPEKVDTEE DGKAEVASEKLTASEQAHPQEPAESAHEPRLSAEYEKVELPSE  381
                  |  |  || |||| |||| ||   | | |||          |||||     |||| ||||||| |
CLONE 72     306  DDLETAEKRKEQEAEKVDEEEKE KTEPASEE         QEPAEDTDQARLSADYEKVELPLE  361

HUM GRAVIN   382  EQVSGSQGPSEEKPAPLATEVFDEKIEVHQEEVVAEVHVSTVEERTEE Q        KTEVEET  437
                   ||      |||| ||||||||||| | ||| |||||||||||  ||| |           || |
CLONE 72     362  DQVGDLEASSEEKCAPLATEVFDEKMEAHQE VVAEVHVSTVE KTEEEQGGGGEAEGGVVVEGT  424

HUM GRAVIN   438  AGSVPAEELVGMDAE PQEAEPAKELVKLKETCVSGEDPTQGADLSPDEKVLSKPPEGVVSEVEM  501
                    | | | |     | ||||||| || |  | |||| | ||  |||| || | | ||| ||||||
CLONE 72     425  GESLPPEKLAEPQ EVPQEAEPAEELMKSREMCVSGGDHTQLTDLSPEEKTLPKHPEGIVSEVEM  488

HUM GRAVIN   502  LSSQERMKVQGSPLKKLFTSTGLKKLSGKKQKGKRGGG DEESGEHTQ VPADSPDSQEEQKGES  564
                  |||||| ||||||||||| | ||||||||||||||||| ||| ||  |     || |  ||||||
CLONE 72     489  LSSQERIKVQGSPLKKLFSSSGLKKLSGKKQKGKRGGGGDEEPGEY QHIHTESPESADEQKGES  552

HUM GRAVIN   565  SASSPEEPEEITCLEKGLAEVQQDGEAEEGATSDGEKKREGVTPWASFKKMVTPKKRVRRPSESD  629
                  |||||||||| ||||||  |  ||||||||||||||||||| |||||||||||||||||||||||
CLONE 72     553  SASSPEEPEETTCLEKGPLEAPQDGEAEEGATSDGEKKREGITPWASFKKMVTPKKRVRRPSESD  617

HUM GRAVIN   630  KEDELDKVKSATLSSTESTASEMQEEMKGSV EEPKPEEPKRKVDTSVSWEALICVGSSKKRARR  693
                  || || |||||||||| || |||| | |  | || ||||||||||||||||||||||||||||
CLONE 72     618  KEEELEKVKSATLSSTDSTVSEMQDEVK TVGEEQKPEEPKRRVDTSVSWEALICVGSSKKRARK  681

HUM GRAVIN   694  RSSSDEEGGPKAMGGDHQKADEAGKDKETGTDGILAGSQEHDPGQGSSSPEQAGSPTEGEGVSTW  758
                   |||| ||||   |||   | || |||| |||   |  || |  ||||||| |||| ||||||||
CLONE 72     682  ASSSDDEGGPRTLGGDSHRAEEASKDKEAGTDAVPASTQEQDQAQGSSSPEPAGSPSEGEGVSTW  746

HUM GRAVIN   759  ESFKRLVTPRKKSKSKLEEKSEDSIAGSGVEH STPDTEPGKEESWVSIKKFIPGRRKKRPDGKQ  822
                  |||||||||||||||||||| |||     ||  ||   ||  |||||||||||||||||| ||||
CLONE 72     747  ESFKRLVTPRKKSKSKLEEKAEDSS    VEQLST EIEPSREESWVSIKKFIPGRRKKRADGKQ  806

HUM GRAVIN   823  EQAPVEDAGPTGANEDDSDVPAVVPLSEYDAVEREKMEAQQAQKGA EQPEQKAATEVSKELSES  886
                  ||| ||| ||   ||||  |||||||||| ||||||||||    |  | |    |  || |||    
CLONE 72     807  EQATVEDSGPVEINEDDPNVPAVVPLSEYNAVEREKMEAQ    GNTELPQLLGAVYVSEELSKT  867

HUM GRAVIN   887  QVHMMAAAVADGTRAATIIEERSPSWISASVTEPLEQVEAEAALLTEEVLEREVIAEEEPPTVTE  951
                   ||    || ||||| |  |||||||||||||||||    ||    ||| |   |||| |   |
CLONE 72     868  LVHTVSVAVIDGTRAVTSVEERSPSWISASVTEPLEHTAGEAMPPVEEVTEKDIIAEETPVL TQ  931

HUM GRAVIN   952  PLPENREARGDTVVSEAELTPEAVTAAETAGPLGSEEGTEASAAEETTEMVSAVSQLTDSPDTTE 1016
                   |||   |  | | ||   | ||||| ||   |  || |||| ||||| ||||||||||||||||
CLONE 72     932  TLPEGKDAHDDMVTSEVDFTSEAVTATETSEALRTEEVTEASGAEETTDMVSAVSQLTDSPDTTE  996

HUM GRAVIN  1017  EATPVQEVEGGVPDIEEQERRTQEVLQAVAEKVKEESQLPGTGGPEDVLQPVQR  AEA ERPEE 1078
                  ||||||||| || | || || ||  ||||| ||||||| | |       | |||    | |  ||
CLONE 72     997  EATPVQEVESGVLDTEEEERQTQAILQAVADKVKEESQVPAT       QTVQRTGSKALEKVEE 1054

HUM GRAVIN  1079  QAEAS GL  KKETDVVLKVDAQEAKTEPFTQGKVVGQTTPESFEKAPQVTESIESSELVTTCQA 1140
                    | |  |   || ||  |   |||  |   ||   || |||| |  | ||        | |||        
CLONE 72    1055  VEEDSEVLASEKEKDVMPKGPVQEAGAEHLAQGSETGQATPESLE VPEVT   ADVDHVATCQ  1114

HUM GRAVIN  1141  ETLAGVKSQEMVMEQAIPPDSVETPTDSETDGSTPVADFDAPGTTQKDEIVEIHEENEVHLVPV  1204
                        | |   ||||  | | || ||||| |||| || | | || | ||           |
CLONE 72    1115    VI  KLQQ LMEQAVAPESSETLTDSETNGSTPLADSDTADGTQQDETIDSQDSKATAAVRQ  1173

HUM GRAVIN  1205  R GTEAEAVPAQKERPPAPSSFVF QEETKEQSKMEDTLEHTDKEVSVETVSILSKTEGTQEAD  1266
                     || ||  |||| |      |  |||  |     | || |  |     |  |  ||  ||
CLONE 72    1174  SQVTEEEAATAQKEEPSTLPNNVPAQEEHGEEPGR DVLEPTQQELTAAAVPVLANTEVGQEGEV 1237

HUM GRAVIN  1267  QYAD EKTKDVPF FEGLEGSIDTGITVSREKVTEVALKGEGTEEAECKKDDALELQSHAKSPPS 1329
                     | || |     |     |   |   |  |   |    |    | |      | |    |  
CLONE 72    1238  DWLDGEKVKEEQEVF   VHS   GPN S QKAADVTYDSEVMGVAGCQEKESTEVQ    SLS  1289

HUM GRAVIN  1330  PVEREMVVQVEREKTEAEPTHVNEEKLEHETAVTVSEEVSKQLLQTVNVPIIDGAKEVSSLEGSP 1394
                    | ||   || || |  |  | ||  | |||    |        |   |     |   || |||
CLONE 72    1290  LEEGEMETDVEKEKRETKPEQVSEEG EQETAAPEHEGTYGKPVLTLDMPSSERGKALGSLGGSP 1353

HUM GRAVIN  1395  PPCLGQEEAVCTKIQVQSSEASFTLTAAAEEEKVLGETANILETGETLEPAGAHLVLEEKSSEKN 1459
                       |  | |   ||||     | || |  |||  ||  | ||||  |  ||||   ||||  
CLONE 72    1354  SLPD QDKAGCIEVQVQSLDTTVTQTAEAV EKVI ETVVISETGESPECVGAHLLPAEKSSATG 1415

HUM GRAVIN  1460  EDFAAHPGEDAVPTGPDCQAKSTPVIVSATTKKGLSSDLEGEKTTSLKWKSDEVDEQVACQEV   1522
                          || || ||  || | | ||       |  || ||   |    | | |   |
CLONE 72    1416  GHWTLQHAEDTVPLGPESQAESIPIIVTPAPESTLHPDLQGEISASQRERSEEEDKPDAGPDAD  1479

HUM GRAVIN  1523   KVSVAIED LEPENGILELETKSSKLVQNIIQTAVDQFVRTEETATEMLTSELQTQAHVIKADS 1585
                   | | |||  |  |  ||||| || | | | |||||||| ||| || |      |||     |||
CLONE 72    1480  GKESTAIEKVLKAEPEILELESKSNKIVLNVIQTAVDQFARTE TAPETHAYDSQTQVPAMQADS 1544

HUM GRAVIN  1586  QDAGQETEKEGEEPQASAQDETPITSAKEESESTAVGQAHSDISKDMSEASEKTMTVEVEGSTVN 1650
                  | | |   |                 |                      |                    
CLONE 72    1545  QGAQQMLDKNESCQDETPSAAAQRGLASPDRSGGMGSASEMLAALAVESAGVKVSIEKLPPQPKD 1609

HUM GRAVIN  1651  DQQLEEVVLPSEEEGGGAGTKSVPEDDGHALLAERIEKSLVEPKEDEKGDDVDDPENQNSALADT 1715
                                       |                        |               |  
CLONE 72    1610  QKEHAADGPQLQSLAQAEASASGNLTKESPDTNGPKLTEEGDPPKVEVQEEEMSTKSVKENKAQA 1674

HUM GRAVIN  1716  DASGGLTKESPDTNGPKQKEKEDAQEVELQEGKVHSESDKAITPQAQEELQKQERESAKSELTES*1780
                         |  
CLONE 72    1675  EEDLQEPKGDLAES*                                                   1687

1     MGAGSSTEQRSPEQPPEGSSTPAEPEPSGGGPSAEAAPDTTADPAIAASD    50
51    PATKLLQKNGQLSTINGVAEQDELSLQEGDLNGQKGALNGQGALNSQEEE   100
101   EVIVTEVGQRDSEDVSERDSDKEMATKSAVVHDITDDGQEENRNIEQIPS   150
151   SESNLEELTQPTESQANDIGFKKVFKFVGFKFTVKKDKTEKPDTVQLLTV   200
201   KKDEGEGAAGAGDHQDPSLGAGEAASKESEPKQSTEKPEETLKREQSHAE   250
251   ISPPAESGQAVEECKEEGEEKQEKEPSKSAESPTSPVTSETGSTFKKFFT   300
301   QGWAGWRKKTSFRKPKEDEVEASEKKKEQEPQKVDTEKDGKAEVASEKLT   350
351   ASEQAHPQEPVESAHEPRLSAEYEKVELPSEEQVSGSQGPSEEKPAPLAT   400
401   EVFDEKIEVHQEEVVAEVHVSTVEERTEEQKTEVEETAGSVPAEELVGMD   450
451   AEPQEAEPAKELVKLKETCVSGEDPTQGADLSPDEKVLSKPPEGVVSEVE   500
501   MLSSQERMKVQGSPLKKLFTSTGLKKLSGKKQKGKRGGGGDEESGEHTQV   550
551   PADSPDSQEEQKGESSASSPEEPEEITCLEKGLAEVQQDGEAEEGATSDG   600
601   EKKREGVTPWASFKKMVTPKKRVRRPSESDKEDELDKVKSATLSSTESTA   650
651   SEMQEEMKGSVEEPKPEEPKRKVDTSVSWEALICVGSSKKRARRRSSSDE   700
701   EGGPKAMGGDHQKADEAGKDKETGTDGILAGSQEHDPGQGSSSPEQAGSP   750
751   TEGEGVSTWESFKRLVTPRKKSKSKLEEKSEDSIAGSGVEHSTPDTEPGK   800
801   EESWVSIKKFIPGRRKKRPDGKQEQAPVEDAGPTGANEDDSDVPAVVPLS   850
851   EYDAVEREKMEAQQAQKGAEQPEQKAATEVSKELSESQVHMMAAAVADGT   900
901   RAATIIEERSPSWISASVTEPLEQVEAEAALLTEEVLEREVIAEEEPPTV   950
951   TEPLPENREARGDTVVSEAELTPEAVTAAETAGPLGSEEGTEASAAEETT  1000
1001  EMVSAVSQLTDSPDTTEEATPVQEVEGGVPDIEEQERRTQEVLQAVAEKV  1050
1051  KEESQLPGTGGPEDVLQPVQRAEAERPEEQAEASGLKKETDVVLKVDAQE  1100
1101  AKTEPFTQGKVVGQTTPESFEKAPQVTESIESSELVTTCQAETLAGVKSQ  1150
1151  EMVMEQAIPPDSVETPTDSETDGSTPVADFDAPGTTQKDEIVEIHEENEV  1200
1201  HLVPVRGTEAEAVPAQKERPPAPSSFVFQEETKEQSKMEDTLEHTDKEVS  1250
1251  VETVSILSKTEGTQEADQYADEKTKDVPFFEGLEGSIDTGITVSREKVTE  1300
1301  VALKGEGTEEAECKKDDALELQSHAKSPPSPVEREMVVQVEREKTEAEPT  1350
1351  HVNEEKLEHETAVTVSEEVSKQLLQTVNVPIIDGAKEVSSLEGSPPPCLG  1400
1401  QEEAVCTKIQVQSSEASFTLTAAAEEEKVLGETANILETGETLEPAGAHL  1450
1451  VLEEKSSEKNEDFAAHPGEDAVPTGPDCQAKSTPVIVSATTKKGLSSDLE  1500
1501  GEKTTSLKWKSDEVDEQVACQEVKVSVAIEDLEPENGILELETKSSKLVQ  1550
1551  NIIQTAVDQFVRTEETATEMLTSELQTQAHMIKADSQDAGQETEKEGEEP  1600
1601  QASAQDETPITSAKEESESTAVGQAHSDISKDMSEASEKTMTVEVEGSTV  1650
1651  NDQQLEEVVLPSEEEGGGAGTKSVPEDDGHALLAERIEKSLVEPKEDEKG  1700
1701  DDVDDPENQNSALADTDASGGLTKESPDTNGPKQKEKEDAQEVELQEGKV  1750
1751  HSESDKAITPQAQEELQKQERESAKSELTES                     1781

(a)
(b)
and co-purification experiments have allowed us to propose
that gravin may function as a scaffold protein that coordi-
nates the intracellular locations of PKA and PKC.
Results
Isolation of gravin clones
In order to isolate cDNAs encoding proteins that poten-
tially bind to the type II regulatory subunit of PKA, RII, a
human fetal brain cDNA library was screened using a mod-
ified overlay procedure, with radiolabeled RIIa as a probe
[27]. Eight RII-binding clones were identified and plaque-
purified, and the ends of each cDNA insert were seq-
uenced. Two of the clones represented known sequences.
One matched MAP2, a previously identified AKAP [28].
The 3′ end of another clone, called HF 9, was identical to a
partial clone encoding a protein called gravin, which was
originally isolated by screening a human umbilical-vein
endothelial cell cDNA library with serum from a myasthe-
nia gravis patient [26]. The other six clones had no homol-
ogy to any sequence in Genbank. 
Further sequencing of clone HF 9 showed that the cDNA
was 3 023 base-pairs (bp) in length and encoded a continu-
ous open reading frame of 651 amino acids. Northern-blot
analysis using a 32P-labelled random-primed 1 676 bp
EcoRI–SpeI fragment of HF 9 as a probe indicated that
gravin mRNA is selectively expressed in certain human
tissues. Two predominant mRNA species of 8.4 kilobases
(kb) and 6.7 kb were detected in all tissues but predomi-
nated in liver, brain and lung, whereas an additional 5.5 kb
mRNA was detected in brain (data not shown). Given the
relatively large sizes of all the gravin mRNAs, we con-
cluded that the HF 9 clone represents a partial transcript.
The 1 676 bp fragment was therefore used to further screen
the human fetal brain cDNA library for more complete
transcripts; five additional clones were obtained that
yielded an additional 600 bp of coding region. As an alter-
native strategy, a human heart cDNA library was screened
with the same 1 676 bp HF 9 fragment. Of the five
hybridizing clones isolated, the longest clone contained a
4 216 bp insert which overlapped with the 5′ end of the
original clone. This provided a contiguous sequence of
6 605 bp which is predicted to encode a protein of 1 780
amino acids (Fig. 1a). 
On the basis of our interaction-cloning strategy, we postu-
lated that the last 651 amino acids of the gravin protein
contain a binding site responsible for association with the
type II regulatory subunit of PKA [17]. We have previ-
ously shown that regions of conserved secondary structure
which are likely to include amphipathic a helices are
responsible for binding to RII [29,30]. Residues 1540–1553
of gravin fulfil these criteria (Fig. 2); this region shows
sequence identity with corresponding regions in other
AKAPs (Fig. 2b), and a helical-wheel plot suggests that
there is a segregation of hydrophobic and hydrophilic side-
chains which would be compatible with the formation of
an amphipathic helix (Fig. 2c). 
Surprisingly, further sequence analysis revealed another
potential function of gravin (Fig. 2a). A search of the
nucleotide database using the complete gravin sequence
showed that the first 1 000 residues are 69 % identical to a
murine mitogenic regulatory gene, SSeCKS [31], which is
also called clone 72 and which has recently been shown to
be a PKC substrate/binding protein (Fig. 1b) [32]. We
therefore postulate that gravin may be a kinase-scaffold
protein that binds both PKA and PKC. 
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Figure 2
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(c)(a)
(b) Gravin  		 (1540–1553)
AKAP79  	 (393–405)
Ht31 		 (494–507)
Gravin
(1540–1553)
Sequence comparison of gravin and AKAP250, and identification of
functional domains. (a) The similarities between AKAP250, the original
gravin fragment and SSeCKS/clone 72. The likely RII-binding site is
shown in light blue and prospective PKC-binding sequences are boxed.
(b) Sequence homology between gravin (residues 1540–1553) and
the RII-binding sequences of two other AKAPs are indicated. Light blue
highlighted areas represent conserved amino acids. (c) A helical-wheel
representation of gravin/AKAP250 residues 1540–1553, drawn as an
a-helix of 3.6 amino acids per turn. The shaded area represents the
hydrophobic residues and the white area the hydrophilic side-chains.
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Gravin is an AKAP
On the basis of our previous structure–function studies on
AKAPs [29,30,33–35], we proposed that residues
1540–1553 of gravin were likely to comprise the RII-
binding site (Fig. 2b,c). In order to test this hypothesis, a
set of recombinant fragments encompassing this region
(Fig. 3a) was generated using the polymerase chain reac-
tion (PCR) and expressed in Escherichia coli using the
pET16b Histag bacterial expression/affinity purification
system (Fig. 3b). A 452-residue fragment encompassing
residues 1130–1582 bound 32P-radiolabeled RIIa in the
overlay, whereas a smaller fragment, residues 1130–1525,
which lacks the proposed RII-binding region, was unable
to bind RIIa (Fig. 3c). 
Two additional experiments provided evidence that the
putative amphipathic helix region was sufficient for RII
binding. A third fragment encompassing residues
1526–1780 of gravin bound RII in the overlay (Fig. 3c),
and a synthetic peptide covering residues 1537–1563
blocked all RII-binding in the overlay (Fig. 3d). In addi-
tion, the anchoring inhibitor peptide Ht31(493–515),
which is a competitive inhibitor of RII/AKAP interactions
[29,36], also blocked RII binding to gravin as assessed by
the overlay assay. The Ht31–Pro control peptide did not
(data not shown). When combined, these results suggest
that gravin is an AKAP and that the principal RII-binding
site involves residues 1537–1563. 
This finding was further substantiated when the binding
affinity of the gravin 1526–1780 fragment for a recombinant
RIIa fragment was measured by surface plasmon resonance.
The binding properties of the immobilized gravin fragment
were measured over a range of concentrations of RIIa 1–45
peptide from 25 to 150 nM (Fig. 4a). Uniform first-order
binding was recorded with a Kass of 16 0006 ± 700 M–1 sec–1
(n = 3) and with a Kdis of 0.016 ± 0.001 M–1 (n = 3; Fig. 4b).
These values were used to calculate a dissociation constant
(KD) of 100 nM (n = 3) for the RII–gravin fragment interac-
tion (Fig. 4b). The nanomolar binding constant for RII and
gravin is consistent with the notion that the proteins may
associate in vivo.
Figure 4
Affinity measurement of the gravin–RIIa
interaction. The binding affinity of a
recombinant RIIa fragment (residues 1–45)
for the gravin 1526–1780 fragment was
measured by surface plasmon resonance. The
gravin fragment was immobilized on the
surface of the IAsys (Fison) cuvette as
described in Materials and methods, and was
incubated with the RIIa fragment over a range
of concentrations (25–150 nM). (a) Extent
measurements (in arc seconds) showing the
binding profiles for selected concentrations of
RII interacting with the immobilized gravin
fragment. (b) The measured on-rates
(M–1 sec–1) are plotted against concentration
of RII 1–45 peptide.
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Figure 3
Recombinant gravin fragments bind specifically to RIIa. Recombinant
fragments of gravin were expressed in E. coli using the pET16b
bacterial expression system and purified on Histag resin. (a) The first
and last residues of each fragment are indicated and the sequence of
the putative RII-binding site is presented. (b) Purified protein (10 mg)
was separated by electrophoresis on 10 % (w/v) SDS–polyacrylamide
gels, and gels were stained with Coomassie blue. Fragment sizes are
indicated above each lane. (c,d) Proteins (2 mg) were separated as
above and electrotransferred to PVDF membranes. RII-binding proteins
were detected by a solid-phase binding assay using 32P-radiolabelled
RIIa as a probe in the absence (c) or presence (d) of excess (10 mM)
gravin 1537–1563 peptide.
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Gravin is a PKC-binding protein
On the basis of sequence homology to SSeCKS/clone 72
(Fig. 2a), we postulated that the amino-terminal regions of
gravin may bind PKC. Therefore, a 290 amino-acid frag-
ment corresponding to residues 265–556 of gravin was
expressed in E. coli (Fig. 5a). The affinity-purified gravin
265–556 fragment bound PKC in a phosphatidylserine-
dependent manner, as assessed by an overlay assay (Fig.
5b,c), whereas a carboxy-terminal fragment, residues
1130–1582, did not (Fig. 5b,c). Binding studies were per-
formed with a mixture of PKC a, b and g isoforms.
Neither of the gravin fragments bound to PKC in the
absence of phosphatidylserine (data not shown), which
confirms other reports that phospholipid is cofactor in the
PKC–binding-protein complex [15,32]. The excessive
refractive properties of the phosphatidylserine moiety pre-
vented affinity measurements of the PKC–gravin interac-
tion by surface plasmon resonance. 
It has been suggested that polybasic regions participate in
formation of a phospholipid bridge between PKC and its
binding proteins [15,32]. We have shown that a polybasic
region on another scaffold protein, AKAP79, forms the
PKC-binding site [24]. Because the AKAP79 32–51 peptide
also blocked the binding of PKC to gravin (Fig. 5d), it
seems that both anchoring proteins bind to a similar site on
PKC. Additional evidence of similarity between gravin and
AKAP79 came from the ability of the gravin 265–556 frag-
ment to inhibit PKC activity towards a peptide substrate
with a half-maximal inhibitory concentration (IC50) of
0.50 ± 0.12 mM (n = 4; Fig. 5e), whereas the RII-binding
peptide did not inhibit PKC (data not shown). There are
two polybasic regions in the gravin 265–556 fragment,
located between residues 295–316 and 514–536 (Fig. 2a).
Interestingly, peptides made from sequences within either
polybasic region blocked PKC–gravin interactions as
assessed by the overlay (data not shown). Collectively,
these experiments show that PKC binds gravin in vitro at
one or more polybasic sites located between residues 265
and 556 of gravin. Furthermore, interaction with gravin
appears to inhibit PKC activity.
Induction of gravin in human erythroleukemia cells
Previous studies have suggested that gravin is expressed
in a variety of cell types, including neurons, fibroblasts
and endothelial cells [26,37]. An immunochemical survey
of cell lines indicated that gravin was expressed in MG-63
Figure 5
Gravin binds to, and inhibits, PKC.
Recombinant fragments of gravin were
expressed and purified as described in
Materials and methods. (a) The amino- and
carboxy-terminal residues of each fragment
are indicated, and the locations of polybasic
regions in the full-length gravin sequence are
indicated by black boxes. (b) Purified protein
(2 mg) was separated by electrophoresis on
10 % (w/v) SDS–polyacrylamide gels and
stained with Coomassie blue. The fragment
sizes are indicated above each lane. (c)
Proteins (1 mg) were electrophoresed,
transferred to nitrocellulose and PKC-binding
proteins were detected by a solid-phase
binding assay using partially purified PKC as
the probe, as described in Materials and
methods. (d) PKC-binding assay in the
presence of excess (1 mM) AKAP79 32–51
peptide. (e) The PKC-inhibition profile of the
gravin 265–556 fragment over a range of
concentrations (0.1–10 mM), using an EGF
receptor peptide as a substrate.
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Figure 6
Induction of gravin expression in HEL cells. HEL cells were grown with or
without 40 nM PMA for 18 h. The supernatants of control and treated lysates
(25 mg) were separated by electrophoresis on a 4–15 % SDS–polyacrylamide
gradient gel and electrotransferred to nitrocellulose filters. The sample sources
are indicated above each lane. (a) Gravin was detected by western blot using
affinity-purified antibodies raised against residues 1130–1780 of the
recombinant protein. (b) PKC-binding proteins were detected by the overlay
assay using a partially purified rabbit-brain PKC preparation as a probe and a
monoclonal antibody that recognizes both a and b PKC. (c) RII-binding
proteins were detected by the RII overlay using rabbit anti-RII antibodies to
detect immobilized RII; the migration position of gravin is indicated.
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cells, HEK-293 cells (data not shown) and human ery-
throleukemia (HEL) cells. Phorbol ester treatment of
HEL cells induces morphological, functional and biochem-
ical changes that are characteristic of macrophage-like cells
[38]. One hallmark of this process is the robust induction of
gravin [26]. We therefore decided to examine the profile of
PKA- and PKC-binding proteins in HEL cells after pro-
longed exposure to phorbol esters. HEL cells were grown
in the presence of 40 nM phorbol myristyl acetate (PMA)
for 18 hours and extracts from control and treated cells
were western blotted with an affinity-purified antibody
raised against residues 1130–1780 of gravin. PMA treat-
ment caused induction of a 250 kDa protein that specifi-
cally reacted with anti-gravin antibodies (Fig. 6a).
Subsequent overlay assays demonstrated that PMA treat-
ment induced the expression of a 250 kDa PKC-binding
protein (Fig. 6b) and an RII-binding protein of the same
size (Fig. 6c). These results confirm that phorbol ester
treatment induces gravin expression in HEL cells and
suggest that native gravin binds PKA and PKC in vitro.
Concomitant with the macrophage-like shift in response
to PMA, HEL cells become more adherent and display a
considerable cytoplasmic spread [38]. This sometimes
results in the formation of actin stress fibers and causes a
general flattening of the cell. In order to establish
whether gravin aligned with the actin cytoskeleton, the
actin in phorbol ester-treated HEL cells was stained with
rhodamine phalloidin. All of the cells displayed a concen-
tration of actin in the periphery (Fig. 7a). In contrast,
gravin staining was predominantly cytoplasmic and only a
subset of the cells (approximately 25 %) expressed large
quantities of gravin (Fig. 7b). Variable levels of gravin
expression were not unexpected, as HEL cells are a het-
erogeneous population at different stages of differentia-
tion [38]. Superimposition of both images shows that
gravin and actin exhibit distinct but overlapping subcellu-
lar locations (Fig. 7c). Control experiments in which cells
were stained with preimmune serum were negative (Fig.
7d). More detailed confocal analysis of HEL cells showed
gravin staining toward the periphery of the cell and
enriched in filopodia at the adherent surface (Fig. 8).
These findings are consistent with the notion that gravin
functions in some capacity to enhance HEL cell adhesion
to the substratum.
Dissection of the gravin signaling complex
Binding studies in vitro suggested that gravin is a kinase-
scaffold protein, so we initiated co-localization experiments
Figure 8
The subcellular distribution of gravin. HEL cells were seeded on
coverslips and grown in the presence of PMA, then stained with
affinity-purified gravin antibodies  and the fluorescence detected as
described for Figure 7. The panels depict sequential 1 mm confocal
sections through an individual cell. 
Figure 7
Gravin in HEL cells. HEL cells were grown on coverslips in the
presence of 40 nM PMA for 18 h. Cells were fixed with 3.7 %
formaldehyde and permeabilized with 100 % acetone at –20 °C. 
(a,c) The actin was stained with rhodamine phalloidin and (b,c) gravin
was stained with affinity-purified antibodies (0.5 mg ml–1) and detected
with a fluorescein-conjugated secondary antibody (1:100). (d) No
specific staining was detected with preimmune serum. Fluorescence
detection was by a Lietz Fluovert-FU confocal photomicroscope with a
63/1.4 N.A. OEL PL lens.
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to determine whether a gravin signaling complex could be
detected in HEL cells. Fixed and permeabilized cells pre-
treated with PMA were overlayed with recombinant RIIa
(Fig. 9). RII binding in situ was detected with antibodies
that specifically recognize murine RII (Fig. 9b) and mimic-
ked the staining pattern for gravin (Fig. 9a,c). As control
experiments confirmed that the anti-murine RII antibodies
did not detect the endogenous human RII (Fig. 9d), we
conclude that the increased RII staining was due to direct
association with gravin. This conclusion is supported by
additional control experiments showing that in situ RII
binding was blocked by incubation with the Ht31 anchor-
ing-inhibitor peptide (data not shown). Parallel experi-
ments which attempted to detect PKC binding by in situ
overlay were unsuccessful.
Finally, the gravin signaling complex was isolated by two
complementary biochemical methods: immunoprecipita-
tion and affinity chromatography on cAMP-agarose.
Immunoprecipitation with anti-gravin antibodies specifi-
cally isolated a 250 kDa protein that could be faintly
detected when gels were stained with Coomassie blue
(data not shown). This 250 kDa protein was present only
in immunoprecipitates using the affinity-purified gravin
antibodies and was not detected in control experiments
using preimmune serum. Western blot and overlay assays
confirmed that the 250 kDa protein was gravin (Fig. 10a),
a PKC-binding protein (Fig. 10b) and an AKAP (Fig. 10c).
Moreover, coprecipitation of the PKA holoenzyme was
demonstrated by detection of the C subunit in fractions
eluted from the immunoprecipitate with cAMP but not in
experimental fractions treated with preimmune serum
(Fig. 10d). We were unable to detect PKA RII subunit in
Figure 9
Fluorescent detection in situ of RII–AKAP complexes. HEL cells were
seeded on coverslips, grown in the presence of PMA, fixed and
permeabilized as described for Figure 7. (a) Gravin was detected
immunochemically as described in Materials and methods. (b)
Unoccupied RII-binding sites were detected by an in situ overlay
procedure described in the Materials and methods. Detection of
anchored murine RIIa was by indirect immunofluorescence using a
Texas red-conjugated secondary antibody. (c) Double staining of RII
and gravin was displayed by superimposing images from the same
focal plane in panels (a) and (b). (d) There was no cross reaction of
the anti-murine RII antibody with the endogenous human RII.
Figure 10
Immunoprecipitation of the gravin signaling complex. Supernatants of
HEL cell lysates grown in the presence of 40 nM PMA were incubated
with 15 mg of anti-gravin antibodies or 15 mg of preimmune IgG.
Immunoprecipitations were performed as described in the Materials
and methods. Control and immunoprecipitated fractions (5 mg) were
separated by electrophoresis on a 4–15 % SDS–polyacrylamide
gradient gel and electrotransferred to nitrocellulose filters. The sample
sources are indicated above each lane. (a) Detection of gravin by
western blot using affinity-purified gravin antibodies. (b) Detection of
PKC-binding proteins by the overlay procedure. (c) Detection of RII-
binding proteins by overlay using affinity-purified antibodies to detect
the immobilized murine RIIa. (d) Catalytic subunit of PKA eluted with
1 mM cAMP from the immune complexes detected using
affinity-purified antibodies to the C subunit of PKA.
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Co-purification of the gravin–RII complex. (a) The R subunits of PKA
were purified from HEL cell lysates by affinity chromatography with
cAMP-agarose. (b) Gravin was detected immunochemically in a
fraction eluted from the column in buffer containing 75 mM cAMP.

AKAP
  250
RIIαcAMP
(a) (b)
200
116
97
66
45
Ly
sa
te
W
as
h
Elu
ate

Gravin
the immunoprecipitates because, with a molecular mass of
54 kDa, it migrates with the same mobility as the
immunoglobulin heavy chain (Fig. 10c). However, the RII
subunit–gravin complex was purified from PMA-induced
HEL cell extracts by affinity chromatography on cAMP-
agarose (Fig. 11a). After extensive washing in high-salt
buffers, gravin was eluted from the affinity resin with
75 mM cAMP (Fig. 11b). Because free gravin does not
react with the affinity resin, we concluded that the protein
detected in the eluate was associated with the regulatory
subunit. Both co-purification techniques strongly suggest
that the PKA holoenzyme is associated with gravin in vivo.
However, PKC was not detected with the gravin fraction
by either method.
Discussion
In this report, we describe the cloning and characterization
of a human kinase-anchoring protein called gravin. The
carboxy-terminal fragment of gravin was originally identi-
fied as a cytoplasmic antigen recognized by myasthenia
gravis sera [26]. We now show that the first half of the full-
length gravin protein is homologous to SSeCKS/clone 72,
a murine protein whose gene was independently cloned
firstly because its mRNA product was transcriptionally
suppressed by Src [31], and secondly because the product
is a PKC substrate/binding protein [32]. Although they are
clearly related, it is unclear whether gravin and
SSeCKS/clone 72 represent human and murine homologs
of the same protein. The first 1 000 residues of the two
proteins share 69 % sequence identity, including selected
regions which show homology to the PKC substrate pro-
teins known as MARCKs [39]. However, the remainder of
each protein sequence is distinct. Also, gravin is a protein
of 1 780 amino acids which migrates with a mobility of
250 kDa, whereas SSeCKS/clone 72 is 1 687 residues and
migrates at 207 kDa [31]. In addition, the identification of
five prospective nuclear localization signals has led to the
idea that SSeCKS is a nuclear protein [32], whereas our
immunochemical data clearly shows that gravin is cyto-
plasmic and likely to be a cytoskeletal component. We
propose that gravin and SSeCKS/clone 72 are members of
an emerging class of mammalian scaffold proteins which
contribute to the coordination and organization of signal
transduction events by bringing kinases together [19].
We propose that residues 1537–1563 of gravin form the
PKA-anchoring site, as a peptide made from this sequence
is sufficient to block binding of the RII subunit of PKA in
the overlay assay, and protein fragments containing this
region bind RII with nanomolar affinities. Because this
sequence is present in the carboxyl terminus of
SSeCKS/clone 72, we predict that SSeCKS/clone 72 will
be an AKAP also. Interestingly, this shared sequence has
10 out of 14 residues which are conserved in the RII-
binding region of another mammalian scaffold protein,
AKAP79, which binds PKA, PKC and PP-2B [14,19,24].
The identification of a conserved RII-binding sequence in
gravin, SSeCKS/clone 72 and AKAP79 was rather surpris-
ing as we have previously proposed that a lack of sequence
identity between the AKAPs is due to a conservation of
only secondary structure in the RII-binding motif [17,29].
Therefore, gravin, SSeCKS/clone 72 and AKAP79 may be
members of a structurally related subfamily of AKAPs
which bind more than one kinase or phosphatase.
Although we have demonstrated that gravin anchors PKA
in vivo, the question of whether it is also an intracellular
PKC-binding protein is not so clear. Three classes of
PKC-binding proteins have been identified by gel overlay
and two-hybrid gene-interaction experiments (reviewed in
[3,6]). PKC substrate/binding proteins [15] and ‘receptors
for activated C-kinase’ (RACKs) [40] have been detected
by gel overlay, whereas ‘proteins that interact with C-
kinase’ (Picks)  have been isolated in two-hybrid screens
[16]. On the basis of the homology to SSeCKS/clone 72,
we would propose that gravin is a PKC substrate/binding
protein. Indeed, we have located a region of 290 amino
acids that supports PKC-binding and blocks PKC activity
in vitro. There is some ambiguity as to where the principal
PKC-binding site(s) are located within this region,
however. It has been suggested that phosphatidylserine
supports a ternary complex of PKC and polybasic regions
on the substrate/binding protein [41]. There are two poly-
basic regions in the gravin 265–556 fragment, both of
which block PKC binding in the overlay assay  (T.M.K.
and J.D.S., unpublished observations). Furthermore, both
polybasic regions (residues 295–316 and 514–536) resem-
ble the PKC-binding site on AKAP79 which also blocks
binding in the overlay assay and inhibits kinase activity
[24]. At the moment, it is unclear how both regions partici-
pate in enzyme binding or whether there are multiple
PKC-binding sites on gravin. 
Despite evidence of PKC binding in vitro, we have been
unable to detect the gravin–PKC complex inside cells.
There are, however, several plausible explanations for
this. First of all, a distinguishing feature of
substrate/binding proteins is that phosphorylation regu-
lates their association with PKC [15]. This implies that
substrate/binding proteins may interact with the kinase
transiently, although how these proteins act to influence
the subcellular location of PKC has yet to be precisely
determined. Consequently, substrate/binding proteins
may merely represent PKC substrates that release the
enzyme slowly once the phosphotransfer reaction is com-
plete [42]. The net effect of such a mechanism would be
that substrate/binding proteins could deplete the pool of
active PKC available for conventional substrates. This
may explain why submicromolar concentrations of the
gravin 265–556 fragment inhibit kinase activity in the
presence of excess peptide substrate. A second possible
explanation for our failure to detect the gravin–PKC
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complex in cells is that the necessary inclusion of deter-
gents in the cell permeabilization and extraction buffers
used to isolate the complex may remove the phospholipid
co-factor that cements the PKC–gravin interaction. A third
possible explanation is that the prolonged exposure to
phorbol esters which is necessary to induce high-level
gravin expression in HEL cells also down-regulates PKC
[43] and undoubtedly decreases the pool of enzyme avail-
able to associate with gravin. Nevertheless, the question of
whether a pool of PKC is perpetually targeted in HEL cells
through association with gravin or other substrate/binding
proteins must remain open until there is definitive evi-
dence that the complex is formed in vivo.
Evidence from two different models points to distinct, yet
related, functions for a gravin signaling complex. A tissue
survey has shown that gravin has a restricted cellular dis-
tribution and is predominantly expressed in fibroblasts,
neurons and cells derived from the neural crest [37]. As
each of these cell types participates in adherent, migratory
or path-seeking functions, it was postulated that gravin
might regulate membrane and/or cytoskeletal events [37].
This view has been further substantiated by our
immunolocalization experiments which suggest that
gravin concentrates PKA in the ruffles and filopodia of
adherent HEL cells. In addition, a pair of reciprocal
results point toward a role in cell adhesion. Phorbol ester-
induced adhesion in HEL cells [26] is concomitant with
increased gravin expression (Fig. 7), whereas loss of an
adherent phenotype upon transformation of REF 52
fibroblasts with a derivative of simian virus 40 (SV40) is
coincident with down-regulation of SSeCKS/clone 72 [32].
As phosphorylation events help to maintain the integrity
of the membrane and its associated cytoskeleton, it is also
tempting to speculate that anchoring of PKA and PKC by
gravin may play a role in adherent processes.
Myasthenia gravis is a disease of neuromuscular transmis-
sion which is generally believed to be due to auto-antibod-
ies to the nicotinic acetylcholine receptor. But myasthenics
also frequently produce antibodies to cytoskeletal compo-
nents that may be physically linked to the receptor [44].
Direct association between the acetylcholine receptor and
gravin is unlikely, however, as gravin is not present at the
neuromuscular junction [37]. Nevertheless, gravin’s sub-
cellular location in HEL cells is consistent with a role in
the modulation of membrane–cytoskeletal events. It is
noteworthy that gravin’s proposed role in the coordination
of PKA and PKC targeting to cytoskeletal components
would be analogous to AKAP79’s role in clustering PKA,
PKC and PP2B at the postsynaptic density, which is a spe-
cialized structure of the dendritic cytoskeleton [14,24,36].
Future studies are planned to determine whether gravin
interacts with additional membrane and/or cytoskeletal
components and whether disruption of kinase anchoring
affects cell shape and motility.
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Materials and methods
Cloning of gravin cDNAs
A 3 023 bp partial cDNA encoding an RII-binding protein was isolated
by expression-cloning from a human fetal brain lZAP cDNA library using
a modified form of the RII-overlay procedure as previously described
[33]. Clones encoding full-length gravin were obtained by screening a
human heart lZAP cDNA library using an a-[32P]dCTP random-primed
1 676 bp EcoRI–SpeI fragment from the original clone as a probe.
Nucleotide sequencing used the Sanger dideoxy method [45] or was
with an Applied Biosystems sequencer (Foster City, California). The
Genbank accession number for the gravin sequence is U81607.
Bacterial expression of recombinant proteins
A 1 953 bp insert encompassing the entire open reading frame of the
original gravin cDNA was subcloned into the bacterial expression vector
pET16b. This was accomplished by amplifying the fragment using PCR
with the original HF 9 clone as the template. Primers were synthesized
that generated an NdeI site at the 5′ end (CCGCCATGGTGCATAT-
GTCCGAGTCCAGTGAGC) and a BamHI site at the 3′ end (GGAG-
GATCCAGAGATTCTGTAGTTCTG) to facilitate subcloning into the
vector. A similar strategy was used to generate the RII-binding site con-
structs encompassing residues 1130–1780, 1130–1525 and
1526–1780 of gravin. The first two constructs shared a common 5′
primer (CCGCCATGGTGCATATGTCCGAGTCCAGTGAGC) but had
distinct 3′ primers: GCGCGGATCCGCACTCACTTTGACCTCCTG
for residues 1130–1780 and GCGCGGATCCGCTATCACGT-
GAGCTTGTGT for residues 1130–1525. The 1526–1780 construct
was amplified using a unique 5′ primer (CCGCCATGGTGCATATG-
GTAGCAATTGAGGATTTAG) in conjunction with the 3′ primer
(GGAGGATCCAGAGATTCTGTAGTTCTG) used to subclone the full-
length clone. Likewise, the gravin 265–556 fragment was generated by
a PCR-based strategy to map the PKC-binding site. This insert was
amplified from the original gravin cDNA using a 5′ primer (CCGCCATG-
GTGCATATGAAAGAGGAAGGAGAAGAG) which encoded an NdeI
site and a 3′ primer (GGAGGATCCAGAGCTGTCCGGAGAATCGGC)
which encompassed a BamHI site.
Each gravin construct was transfected into E. coli and the recombinant
Histag fusion proteins were induced using IPTG. Each recombinant
protein was purified according to previously published methods [14]. The
1130–1780 gravin fragment was used for production of a polyclonal anti-
body (Bethyl Labs, Montgomery, Texas), hereafter referred to as R3698.
Surface plasmon resonance measurements
A recombinant fragment encompassing residues 1526–1780 of gravin
was coupled to a carboxymethyldextran IAsys cuvette using standard
EDC/NHS coupling chemistry [46]. The cuvette was activated by treat-
ing with 0.4 M EDC/0.1 M NHS for 8 min and washed extensively with
PBST (PBS + 0.05 % Tween-20). Coupling of the gravin 1526–1780
fragment (25 mg ml–1) was accomplished in 10 mM formate buffer,
pH 3.6 for 10 min at room temperature. Uncoupled protein was washed
out with PBST and free amines were blocked with 1 M ethanolamine,
pH 8.5 for 2 min at room temperature. After washing with PBST, a
stable base-line was established for 10 min before data collection. All
binding experiments were performed with a recombinant fragment of
RIIa (RII 1–45) which binds AKAPs with a similar affinity to that of the
full-length protein. Previous experiments have indicated that release of
RIIa 1–45 from the binding surface can be performed under conditions
that are less harmful to the immobilized anchoring protein than studies
using full-length RII. Binding experiments were performed over a range
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of concentrations from 25 to 150 nM in volumes of 200 ml. The binding
surface was regenerated between binding measurements using 60 %
ethanol with no decrease in extent measurements over the duration of
an experiment. Data collection was over 3 sec intervals and was ana-
lyzed using the FastfitTM software which was provided with the IAsys
instrument. 
Solid-phase overlays and western blots
RII overlays, western blots and PKC overlays were performed essen-
tially as described previously [24,47]. Immunochemical detection of RII
used an affinity-purified rabbit antibody to murine RIIa. The PKC overlay
was probed with a monoclonal antibody that recognizes both a and b
PKC (Transduction Labs, Lexington, Kentucky). The catalytic subunit of
PKA was detected using affinity-purified antibodies to an amino-termi-
nal peptide of the human PKA C subunit (gift from Steven Pelech,
Kinetek Biotechnology Corp, Vancouver, Canada).
PKC inhibition assay
PKC was assayed as described [48] in a reaction containing 40 mM
HEPES (pH 7.5), 10 mM MgCl2, 0.3 mM CaCl2, 1 mM DTT, 100 mM g-
[32P]ATP (500 cpm pmol–1), phosphatidylserine (20 mg ml–1), and epi-
dermal growth factor receptor peptide (VRKRTLPRL) as a substrate, at
30 °C for 10 min. PKC bII (20 ng ml–1) was diluted 1:10 in 20 mM Tris
(pH 7.9), 1 mg ml–1 bovine serum albumin (BSA) and 1 mM DTT. Inhi-
bition constants (IC50) were determined over an inhibition concentra-
tion range of 0.1–10 mM gravin 265–556 fragment.
Cell culture and preparation of cell lysates
Human erythroleukemia (HEL 92.1.7, ATCC TIB 180) cells were grown
in RPMI 1640 containing 12 % fetal calf serum and 4 mM glutamine.
Gravin expression was induced by culturing with 40 nM phorbol myris-
tate acetate for 18 h. Cell lysates were prepared from either adherent
cells grown in the presence of PMA, rinsed with PBS and scraped from
the interior of 150 cm2 flasks, or from suspension cultures of HEL cells
grown in the absence of PMA. Cell pellets were washed twice with PBS
prior to resuspension in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM
EDTA, 0.25 % Triton X-100, 0.05 % Tween-20, 0.02 % NaN3, 10 mM
benzamidine, 2 mg ml–1 pepstatin, 2 mg ml–1 leupeptin, 4 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride (lysis buffer) and incu-
bation on ice for 10 min. The extract was then centrifuged for 10 min at
16 000 × g at 4 °C and the cell lysate supernatant was collected. Protein
concentrations were measured using the Bio-Rad DC Protein Assay kit. 
Immunocytochemistry and in situ RII overlays
HEL cells were grown on glass coverslips in the presence of 40 nM
PMA for 18 h, rinsed with PBS, fixed in 3.7 % formaldehyde and
extracted in –20 °C absolute acetone. Cells were rehydrated for 1 h in
PBS plus 0.2 % BSA and then incubated with either affinity-purified anti-
gravin antibody R3698 at 0.5 mg ml–1 or pre-immune IgG at 0.5 mg ml–1.
After 1 h, the coverslips were carefully washed in PBS plus 0.2 % BSA
and incubated with either a mixture of FITC-conjugated donkey anti-
rabbit secondary antibody (1:100; Jackson ImmunoReasearch Laborato-
ries, West Grove, Pennsylvania) and rhodamine-conjugated phalloidin
(1 unit per coverslip; Molecular Probes, Eugene, Oregon) or secondary
antibody alone. In situ RII overlays were performed essentially as
described [34]. Prior to incubation with primary antibody, cells were
incubated with 80 nM recombinant murine RIIa for 2 h and unbound RII
was removed by washing three times in PBS and 0.2 % BSA. The immo-
bilized RIIa was detected immunochemically with affinity-purified goat
anti-murine RII (1 mg ml–1) and Texas red-conjugated donkey anti-goat
secondary IgG (1:100; Jackson ImmunoReasearch Laboratories, West
Grove, Pennsylvania). Control coverslips were treated with the antibody
to RII in the absence of exogenous murine RII. Cells were examined
using a Leica confocal laser scanning system equipped with a Leitz Flu-
overt-FU inverted microscope and an argon/krypton laser.
Immunoprecipitation
HEL cell lysates (200 ml of 15 mg ml–1), prepared as described above,
were incubated with either 15 mg of affinity-purified anti-gravin
antibodies, or 15 mg of pre-immune IgG, at 4 °C for 18 h. Immune com-
plexes were isolated by the addition of 200 ml 10 % (v/v)
protein A–Sepharose CL-4B (Sigma, St Louis, Missouri) which had
been pre-equilibrated in lysis buffer. Following incubation at 4°C for
90 min, the beads were washed once in 0.5 M NaCl lysis buffer and four
times in excess 20 mM TrisHCl, pH 7.4, 150 mM NaCl. The PKA cat-
alytic subunit was released from the immune complex by incubating the
protein A beads in 200 ml 1 mM cAMP, 20 mM TrisHCl, pH 7.4, 150
mM NaCl for 15 min. The eluate was TCA-precipitated prior to analysis
on a 4–15 % SDS–polyacrylamide gel, electroblotted onto nitrocellu-
lose and the C subunit was detected, as previously described [33]. For
the immunoprecipitation and detection of gravin, elution was accom-
plished by boiling the washed beads in SDS–PAGE sample buffer, fol-
lowed by separation of proteins on a 4–15 % denaturing gel (5mg per
lane), transfer to nitrocellulose and analysis by gravin western blot, PKC
overlay or RII-overlay–western as described above and previously [24].
Copurification of gravin and RII on cAMP-sepharose
HEL cell lysates (400 ml of 15 mg ml–1, prepared as described above
with the addition of 10 mM IBMX to the buffer), were incubated with
200 ml packed cAMP-agarose (Sigma, St Louis, Missouri) which had
been equilibrated in lysis buffer with 10 mM IBMX. The slurry was
gently mixed for 18 h at 4 °C and then washed with 1.5 ml lysis buffer
plus 1 M NaCl followed by four 1.5 ml washes with 20 mM TrisHCl,
pH 7.4, 150 mM NaCl. Elution was accomplished by incubating the
beads in 0.5 ml 75 mM cAMP, 20 mM TrisHCl, pH 7.4, 150 mM NaCl
for 30 min at room temperature. The final wash and the eluate were
TCA-precipitated and the entire sample loaded into a single lane on a
4–15 % SDS–polyacrylamide gel. The separated proteins were blotted
onto nitrocellulose and gravin was identified by western analysis as
described above.
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